Evidence map›Paper›PMID 28042873›Full record

ArticleActa pharmacologica Sinica2017

A mini-network balance model for evaluating the progression of cardiovascular complications in Goto-Kakizaki rats.

Hao Jiang, Yu-Hao Wang, Chun-Xiang Wei, Xue Zhang, Hao-Chen Liu, Xiao-Quan Liu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hao JiangCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
Yu-Hao WangCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
Chun-Xiang WeiCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
Xue ZhangCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
Hao-Chen LiuCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
Xiao-Quan LiuCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular complications represent a leading cause of mortality in patients with type 2 diabetes mellitus (T2DM). During such complicated progression, subtle variations in the cardiovascular risk (CVR)-related biomarkers have been used to identify cardiovascular disease at the incipient stage. In this study we attempt to integrally characterize the progression of cardiovascular complications and to assess the beneficial effects of metformin combined with salvianolic acid A (Sal A), in Goto-Kakizaki (GK) rats with spontaneous T2DM. The rats were treated with metformin (200 mg·kg

Indexed as

Models, BiologicalAlkenesAnimalsCardiovascular DiseasesDiabetes ComplicationsDiabetes Mellitus, Type 2Disease ProgressionDrug Therapy, CombinationHypoglycemic AgentsMetforminPolyphenolsRats, WistarAlkenesHypoglycemic AgentsMetforminPolyphenolssalvianolic acid

Identifiers

PMID28042873
PMCPMC5342663
OpenAlexW2562917271

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.